RE: news: Artikel-DJ_IRW_PRESS_Telesta_Google translation;
TELESTA Therapeuticals is a leading Canadian biotechnology company specializing in the clinical development, manufacturing and marketing of innovative therapeutics for the global healthcare market. The main product of TELESTA is the medicine for the treatment of non-muscle-MCNA bladder cancer. The drug is already in Phase III clinical trials and is therefore well advanced. TELESTA now looking for new and innovative solutions for the delivery MCNA and tries to expand its product pipeline.
Middle of last year sold TELESTA animal health division for 61 million Canadian dollars in Vetoquinol and thus repaid debt in the amount of 47.9 million. In September 2014, the company also implemented a capital increase, which further $ 5.8 million flushed into the war chest. End of September had TELESTA 10.5 million cash and a cost of about $ 1.5 million a month. It is speculated for a while now that the company could enter into a development partnership with a major pharmaceutical companies regarding the US rights for MCNA. This can rinse immediately an average double-digit millions in cash and generate more future revenues.
After the Phase I Phase II studies how to MCNA were successfully completed, first a phase III study of 129 patients at 25 medical institutions was conducted in the US and Canada. Within a year, the symptom-free survival rate was 25%. In the other patients on the MCNA positive step ruled the cancer still significantly slower. Side effects were hereby limited to mild to moderate. The marketing authorization application is to be submitted to the US Food and Drug Administration (Food and Drug Administration) by March 2015.
Compared with other companies such as Galena Biopharma, Oncothyren or Endocyte whose drugs are in clinical phase III, TELESTA is significantly undervalued. It could be that MCNA also suitable for treating other cancers. It is reasonable to hope for positive news regarding a partnership and approval of MCNA. Investors should stick to this initial situation necessarily there. The stock is still a sale and can quickly reach 0.4 euros. Another company which is immense growth is still in its infancy Clear TV from the US.